

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 描述 | Calcipotriol is a synthetic VitD3 analogue with a high affinity for the vitamin D receptor. |
| Concentration | Treated Time | Description | References | |
| Human rectal epithelial cells | 1 µM | 15 hours | Calcipotriol reduced crypt cell production rate by 52% from mean (SEM) 5-29(1.18) to 256(0.80)cells/crypt/hour (p<0.01) | Gut. 1994 Dec;35(12):1742-6. |
| HepG2 cells | 0.1, 1, 10 nM | 2 hours | To investigate the impact of CYP3A4 on the VDR-induction ability of 1,25(OH)2D3, results showed that CYP3A4 inhibited the induction of VDR by 1,25(OH)2D3 | J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13733. |
| AGS cells | 500 nM | 24 hours | Significantly inhibited CAF-induced oxaliplatin resistance | Acta Pharmacol Sin. 2023 Jan;44(1):178-188. |
| HGC-27 cells | 500 nM | 24 hours | Significantly inhibited CAF-induced oxaliplatin resistance | Acta Pharmacol Sin. 2023 Jan;44(1):178-188. |
| C2C12 cells | 10 nM | 8 days | To investigate the effects of vitamin D and testosterone on muscle differentiation, results showed that testosterone enhanced the inducing effects of VD on VDR, AR, P-AKT, PGC1α, Beclin1 and LC3B | J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13733. |
| Administration | Dosage | Frequency | Description | References | ||
| C57BL/6J mice | Form deprivation myopia (FDM) model | Intraperitoneal injection | 0.1 mg/kg or 0.5 mg/kg | Daily injections for 4 weeks | To assess the inhibitory effect of Calcipotriol on FDM development. Results showed that Calcipotriol significantly suppressed FDM-induced myopia progression and upregulated scleral Col1α1 gene expression levels. | Invest Ophthalmol Vis Sci. 2023 Feb 1;64(2):2. |
| C57BL/6 mice | MC903-induced skin inflammation model | Topical application | 0.5 nmol/ear | Daily for 14 days | To investigate the protective effect of DMOG on MC903-induced skin inflammation. DMOG significantly attenuated MC903-induced skin inflammation, accompanied by downregulation of TSLP and IL-33. | Front Immunol. 2024 Mar 1;15:1330011 |
| C57BL/6J mice | Nur77 knockout mice | Intraperitoneal injection | 60 µg/kg | Three times a week for a total of 12 weeks | Calcipotriol combined with iBRD9 treatment reduced the body weight and body fat percentage in Nur77 knockout mice, regulated the gut microbiota, improved intestinal mucosal barrier function, reduced LPS absorption into the blood, and alleviated obesity | Int J Obes (Lond). 2020 May;44(5):1052-1061 |
| BALB/c-nude mice | Gastric cancer xenograft model | Intraperitoneal injection | 60 mg/kg | Three times a week for 16 days | Significantly inhibited tumor growth and enhanced the anti-tumor effect of oxaliplatin | Acta Pharmacol Sin. 2023 Jan;44(1):178-188. |
| Mice | Sod1 knockout mice (SKO) | Intraperitoneal injection | 60 μg/kg | Three times a week, lasting until 28 weeks of age | To investigate the effects of Calcipotriol on muscle function, results showed that Calcipotriol restored grip strength in male SKO mice, increased muscle protein synthesis and mitochondrial biogenesis, while decreasing inflammation and atrogenes expression | J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13733. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.42mL 0.48mL 0.24mL |
12.12mL 2.42mL 1.21mL |
24.24mL 4.85mL 2.42mL |
|
| CAS号 | 112965-21-6 |
| 分子式 | C27H40O3 |
| 分子量 | 412.6 |
| SMILES Code | O[C@H]1C[C@H](O)C(/C(C1)=C\C=C2[C@]3([H])CC[C@H]([C@H](C)/C=C/[C@H](C4CC4)O)[C@@]3(C)CCC\2)=C |
| MDL No. | MFCD00866630 |
| 别名 | MC 903; Calcipotriene; Sorilux.; Psorcutan; PRI 2201; Dovonex; Daivonex; CCRIS 7700; Calcitrene; Calciptriol |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
| 溶解方案 |
DMSO: 105 mg/mL(254.48 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 45 mg/mL(109.06 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1